Floatz logo

Cytosin-Arabinosid

Chronic Myelogenous Leukemia

M.D. Anderson Cancer CenterPhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

85 Active assets in the Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →